Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Labrys Biologics
Private Company Edition: venBio’s new fund plus Ysios Capital’s recent €216m ($260m) fund adds up to $810m in fresh venture capital for life science companies. Also, Nikang and Esco attracted $200m each in VC investment, Pulmocide closed a $92m series C round and Stablix launched with $63m.
Under emerging pricing strategy, Lilly will provide Emgality free for up to 12 months to commercially insured patients; Amgen has similar program for Aimovig.
Unlike the migraine space, there is only one competitor for Teva's CGRP inhibitor in cluster headaches, but that opportunity narrowed with fremanezumab's failure in chronic cluster headaches, though a trial in episodic cluster headaches is ongoing.
Emerging Company Profile: Pionyr Immunotherapeutics exec who once led early development for Merck's PD-1 inhibitor Keytruda explains the San Francisco start-up's approach to rebalancing the tumor's microenvironment in order to improve outcomes.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.